title: Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma.
abstract: In the prospective phase 3 HOVON-50/GMMG-HD3 trial, patients randomized to TAD (thalidomide, doxorubicin, dexamethasone) had a significantly higher response rate (at least PR) after induction compared with patients randomized to VAD (vincristine, adriamycin, dexamethasone, 72% vs. 54%, p<0.001). Complete remission (CR) and very good partial remission (VGPR) were also higher after TAD. After High Dose melphalan 200mg/m(2) response was comparable in both arms, 76% and 79% respectively. However, CR plus VGPR were significantly higher in the patients randomized to TAD (49% vs. 32%, p<0.001). CTC grade 3-4 adverse events were similar in both arms.
authors.affiliation: Department of Hematology, University Medical Center, Utrecht, The Netherlands. h.lokhorst@umcutrecht.nl
authors.forename: Henk M
authors.initials: HM
authors.lastname: Lokhorst
authors.forename: Ingo
authors.initials: I
authors.lastname: Schmidt-Wolf
authors.forename: Pieter
authors.initials: P
authors.lastname: Sonneveld
authors.forename: Bronno
authors.initials: B
authors.lastname: van der Holt
authors.forename: Hans
authors.initials: H
authors.lastname: Martin
authors.forename: Rene
authors.initials: R
authors.lastname: Barge
authors.forename: Uta
authors.initials: U
authors.lastname: Bertsch
authors.forename: Jana
authors.initials: J
authors.lastname: Schlenzka
authors.forename: Gerard M J
authors.initials: GM
authors.lastname: Bos
authors.forename: Sandra
authors.initials: S
authors.lastname: Croockewit
authors.forename: Sonja
authors.initials: S
authors.lastname: Zweegman
authors.forename: Iris
authors.initials: I
authors.lastname: Breitkreutz
authors.forename: Iris
authors.initials: I
authors.lastname: Breitkreuz
authors.forename: Peter
authors.initials: P
authors.lastname: Joosten
authors.forename: Christof
authors.initials: C
authors.lastname: Scheid
authors.forename: Marinus
authors.initials: M
authors.lastname: van Marwijk-Kooy
authors.forename: Hans-Juergen
authors.initials: HJ
authors.lastname: Salwender
authors.forename: Marinus H J
authors.initials: MH
authors.lastname: van Oers
authors.forename: Ron
authors.initials: R
authors.lastname: Schaafsma
authors.forename: Ralph
authors.initials: R
authors.lastname: Naumann
authors.forename: Harm
authors.initials: H
authors.lastname: Sinnige
authors.forename: Igor
authors.initials: I
authors.lastname: Blau
authors.forename: Michel
authors.initials: M
authors.lastname: Delforge
authors.forename: Gregor
authors.initials: G
authors.lastname: Verhoef
authors.forename: Okke
authors.initials: O
authors.lastname: de Weerdt
authors.forename: Pierre
authors.initials: P
authors.lastname: Wijermans
authors.forename: Shulamiet
authors.initials: S
authors.lastname: Wittebol
authors.forename: Ulrich
authors.initials: U
authors.lastname: Duersen
authors.forename: Edo
authors.initials: E
authors.lastname: Vellenga
authors.forename: Hartmut
authors.initials: H
authors.lastname: Goldschmidt
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008495:Medical Oncology / Q000379:methods*; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D012074:Remission Induction; D013792:Thalidomide / Q000627:therapeutic use*; D013866:Thioguanine / Q000627:therapeutic use; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D020533:Angiogenesis Inhibitors; D003561:Cytarabine; D013792:Thalidomide; D014750:Vincristine; D003907:Dexamethasone; D013866:Thioguanine; D003630:Daunorubicin